Whady Hueb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3911920/publications.pdf

Version: 2024-02-01

117453 39575 9,279 137 34 94 citations g-index h-index papers 174 174 174 7099 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Strategies for Multivessel Revascularization in Patients with Diabetes. New England Journal of Medicine, 2012, 367, 2375-2384.	13.9	1,573
2	Initial Invasive or Conservative Strategy for Stable Coronary Disease. New England Journal of Medicine, 2020, 382, 1395-1407.	13.9	1,508
3	Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet, The, 2009, 373, 1190-1197.	6.3	649
4	Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet, The, 2018, 391, 939-948.	6.3	506
5	Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet, The, 1995, 346, 1184-1189.	6.3	463
6	Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS II). Circulation, 2007, 115, 1082-1089.	1.6	392
7	The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease. Journal of the American College of Cardiology, 2004, 43, 1743-1751.	1.2	347
8	Ten-Year Follow-Up Survival of the Medicine, Angioplasty, or Surgery Study (MASS II). Circulation, 2010, 122, 949-957.	1.6	284
9	The Medicine, Angioplasty or Surgery Study (MASS): A prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. Journal of the American College of Cardiology, 1995, 26, 1600-1605.	1.2	282
10	Long-Term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Multivessel Coronary Artery Disease. Circulation, 2008, 118, 1146-1154.	1.6	266
11	Percutaneous Coronary Intervention Outcomes in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia. JAMA Internal Medicine, 2014, 174, 232.	2.6	245
12	Long-Term Survival Following MultivesselÂRevascularization in PatientsÂWith Diabetes. Journal of the American College of Cardiology, 2019, 73, 629-638.	1.2	190
13	One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: A meta-analysis of individual patient data from randomized clinical trials. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 512-519.	0.4	148
14	Effects of Optimal Medical Treatment With or Without Coronary Revascularization on Angina and Subsequent Revascularizations in Patients With Type 2 Diabetes Mellitus and Stable Ischemic Heart Disease. Circulation, 2011, 123, 1492-1500.	1.6	108
15	Five-Year Follow-Up of a Randomized Comparison Between Off-Pump and On-Pump Stable Multivessel Coronary Artery Bypass Grafting. The MASS III Trial. Circulation, 2010, 122, S48-S52.	1.6	105
16	Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 2018, 72, 386-398.	1,2	89
17	Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS): A Prospective, Randomized Trial of Medical Therapy, Balloon Angioplasty, or Bypass Surgery for Single Proximal Left Anterior Descending Coronary Artery Stenosis. Circulation, 1999, 100, II-107-II-113.	1.6	70
18	Quality of life in patients with symptomatic multivessel coronary artery disease: A comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial. International Journal of Cardiology, 2007, 116, 364-370.	0.8	70

#	Article	IF	Citations
19	Pulmonary function after coronary artery bypass surgery. Respiratory Medicine, 1997, 91, 629-633.	1.3	64
20	TCF7L2 Polymorphism rs7903146 Is Associated with Coronary Artery Disease Severity and Mortality. PLoS ONE, 2009, 4, e7697.	1,1	56
21	Effect of Complete Revascularization on 10-Year Survival of Patients With Stable Multivessel Coronary Artery Disease. Circulation, 2012, 126, S158-63.	1.6	56
22	Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial. American Heart Journal, 2013, 166, 250-257.	1.2	54
23	SYNTAX Score and Long-TermÂOutcomes. Journal of the American College of Cardiology, 2017, 69, 395-403.	1.2	54
24	In Vitro Simultaneous Transfer of Lipids to HDL in Coronary Artery Disease and in Statin Treatment. Lipids, 2009, 44, 917-24.	0.7	52
25	Relationship Between Pleural Effusion and Pericardial Involvement After Myocardial Revascularization. Chest, 1994, 105, 1748-1752.	0.4	51
26	Reduced expression of systemic proinflammatory and myocardial biomarkers after off-pump versus on-pump coronary artery bypass surgery: A prospective randomized study. Journal of Critical Care, 2010, 25, 305-312.	1.0	50
27	Relationship Between Pleural Changes after Myocardial Revascularization and Pulmonary Mechanics. Chest, 1992, 102, 1333-1336.	0.4	48
28	The Effect of Age on Outcomes of Coronary Artery Bypass Surgery Compared With Balloon Angioplasty or Bare-Metal Stent Implantation Among Patients With Multivessel Coronary Disease. Journal of the American College of Cardiology, 2012, 60, 2150-2157.	1.2	44
29	Coronary Revascularization (Surgical or Percutaneous) Decreases Mortality After the First Year in Diabetic Subjects but not in Nondiabetic Subjects With Multivessel Disease: An Analysis From the Medicine, Angioplasty, or Surgery Study (MASS II). Circulation, 2006, 114, I-420-I-424.	1.6	43
30	SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization in the FREEDOM Trial. Journal of the American College of Cardiology, 2018, 72, 2826-2837.	1.2	42
31	Impact of Diabetes on Five-Year Outcomes of Patients With Multivessel Coronary Artery Disease. Annals of Thoracic Surgery, 2007, 83, 93-99.	0.7	39
32	Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. Kidney International, 2016, 90, 411-421.	2.6	38
33	Factors Related to the Selection of Surgical Versus Percutaneous Revascularization in Diabetic Patients With Multivessel Coronary Artery Disease in the BARI 2D (Bypass Angioplasty) Tj ETQq1 1 0.784314 rgBT 384-392.	lOverlock	10 Tf 50 1
34	Clinical Judgment and Treatment Options in Stable Multivessel Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 48, 948-953.	1.2	35
35	Impact of number of vessels disease on outcome of patients with stable coronary artery disease: 5-year follow-up of the Medical, Angioplasty, and bypass Surgery Study (MASS). European Journal of Cardio-thoracic Surgery, 2008, 33, 349-354.	0.6	34
36	The Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial: Clinical and angiographic profile at study entry. American Heart Journal, 2012, 164, 591-599.	1.2	34

#	Article	IF	CITATIONS
37	Troponin in diabetic patients with and without chronic coronary artery disease. BMC Cardiovascular Disorders, 2015, 15, 72.	0.7	34
38	Clinical significance of chronic myocardial ischemia in coronary artery disease patients. Journal of Thoracic Disease, 2019, 11, 1005-1015.	0.6	34
39	Influence of Atelectasis on Pulmonary Function After Coronary Artery Bypass Grafting. Chest, 1993, 104, 434-437.	0.4	33
40	Efeitos do uso da adrenalina na anestesia local odontol \tilde{A}^3 gica em portador de coronariopatia. Arquivos Brasileiros De Cardiologia, 2007, 88, 545-551.	0.3	33
41	Cost-Effectiveness Analysis for Surgical, Angioplasty, or Medical Therapeutics for Coronary Artery Disease. Circulation, 2012, 126, S145-50.	1.6	33
42	TCF7L2variant genotypes and type 2 diabetes risk in Brazil: significant association, but not a significant tool for risk stratification in the general population. BMC Medical Genetics, 2008, 9, 106.	2.1	32
43	Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery. Journal of Cardiothoracic Surgery, 2010, 5, 91.	0.4	32
44	Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment. Journal of the American College of Cardiology, 2004, 43, 2225-2232.	1.2	30
45	Plasma kinetics of a cholesterol-rich emulsion in subjects with or without coronary artery disease. Journal of Lipid Research, 2003, 44, 464-469.	2.0	29
46	Effect of Hypoglycemic Agents on Ischemic Preconditioning in Patients With Type 2 Diabetes and Symptomatic Coronary Artery Disease. Diabetes Care, 2013, 36, 1654-1659.	4.3	29
47	Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease. Thrombosis Research, 2010, 125, 61-66.	0.8	28
48	Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2015, 14, 107.	2.7	26
49	Relative Cost Comparison of Treatments for Coronary Artery Disease: The First Year Follow-Up of MASS II Study. Circulation, 2003, 108, 21II–23.	1.6	24
50	Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris. Coronary Artery Disease, 2007, 18, 55-59.	0.3	24
51	Cancer-related deaths among different treatment options in chronic coronary artery disease. Coronary Artery Disease, 2012, 23, 79-84.	0.3	24
52	Association Between Stress Testing–Induced Myocardial Ischemia and Clinical Events in Patients With Multivessel Coronary Artery Disease. JAMA Internal Medicine, 2019, 179, 1345.	2.6	24
53	Acute pleuropulmonary complications detected by computed tomography following myocardial revascularization. Revista Do Hospital Das Clinicas, 2002, 57, 135-142.	0.5	22
54	Effect of glycoprotein IIIa PlA2 polymorphism on outcome of patients with stable coronary artery disease and effect of smoking. American Journal of Cardiology, 2004, 93, 1469-1472.	0.7	21

#	Article	IF	CITATIONS
55	Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease. Thrombosis Research, 2006, 118, 679-683.	0.8	21
56	Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 1443-1449.	0.4	21
57	Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization. Thrombosis Research, 2007, 121, 25-32.	0.8	20
58	Accuracy of Myocardial Biomarkers in the Diagnosis of Myocardial Infarction After Revascularization as Assessed by Cardiac Resonance: The Medicine, Angioplasty, Surgery Study V (MASS-V) Trial. Annals of Thoracic Surgery, 2016, 101, 2202-2208.	0.7	20
59	The Effects of Glibenclamide, a KATP Channel Blocker, on the Warm-Up Phenomenon. Annals of Noninvasive Electrocardiology, 2005, 10, 356-362.	0.5	18
60	Qualidade de vida após revascularização cirúrgica do miocárdio com e sem circulação extracorpórea. Arquivos Brasileiros De Cardiologia, 2008, 91, 217-22, 238-44.	0.3	18
61	VATS for complete dissection of LIMA in minimally invasive coronary artery bypass grafting. Annals of Thoracic Surgery, 1997, 63, S110-S113.	0.7	17
62	LDL concentration is correlated with the removal from the plasma of a chylomicron-like emulsion in subjects with coronary artery disease. Atherosclerosis, 2002, 161, 447-453.	0.4	17
63	Qualidade de vida após revascularização cirúrgica do miocárdio, angioplastia ou tratamento clÃnico. Arquivos Brasileiros De Cardiologia, 2007, 88, 537-44.	0.3	17
64	Type 2 diabetes mellitus and myocardial ischemic preconditioning in symptomatic coronary artery disease patients. Cardiovascular Diabetology, 2015, 14, 66.	2.7	17
65	Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: a prospective randomized study. Coronary Artery Disease, 2009, 20, 100-105.	0.3	16
66	The effect of internal thoracic artery grafts on long-term clinical outcomes after coronary bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 829-835.	0.4	16
67	Higher incidence of death in multi-vessel coronary artery disease patients associated with polymorphisms in chromosome 9p21. BMC Cardiovascular Disorders, 2012, 12, 61.	0.7	16
68	Long-term analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial. European Heart Journal, 2013, 34, 3370-3377.	1.0	16
69	Impact of Chronic Kidney Disease on Long-Term Outcomes in Type 2 Diabetic Patients With Coronary Artery Disease on Surgical, Angioplasty, or Medical Treatment. Annals of Thoracic Surgery, 2016, 101, 1735-1744.	0.7	16
70	Death and Myocardial Infarction Following Initial Revascularization Versus Optimal Medical Therapy in Chronic Coronary Syndromes With Myocardial Ischemia: A Systematic Review and Metaâ€Analysis of Contemporary Randomized Controlled Trials. Journal of the American Heart Association, 2021, 10, e019114.	1.6	15
71	Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease. JAMA Network Open, 2020, 3, e1919666.	2.8	14
72	Detection of retained surgical sponge by transthoracic and transesophageal echocardiography. Journal of the American Society of Echocardiography, 2003, 16, 1191-1193.	1.2	13

#	Article	IF	Citations
73	Association between UCP2A55V polymorphism and risk of cardiovascular events in patients with multi-vessel coronary arterial disease. BMC Medical Genetics, 2013, 14, 40.	2.1	13
74	Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial. Nephrology Dialysis Transplantation, 2020, 35, 1369-1376.	0.4	13
75	Impact of metabolic syndrome on the outcome of patients with stable coronary artery disease: 2-year follow-up of the MASS II study. Coronary Artery Disease, 2008, 19, 383-388.	0.3	12
76	Preoperative B-type natriuretic peptide, and not the inflammation status, predicts an adverse outcome for patients undergoing heart surgery \hat{a} . Interactive Cardiovascular and Thoracic Surgery, 2011, 12, 778-783.	0.5	12
77	Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: Effect of age in the Medicine, Angioplasty, or Surgery Study II trial. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 1105-1112.	0.4	12
78	Effects of Glycemic Control upon Serum Lipids and Lipid Transfers to HDL in Patients with Type 2 Diabetes Mellitus: Novel Findings in Unesterified Cholesterol Status. Experimental and Clinical Endocrinology and Diabetes, 2015, 123, 232-239.	0.6	12
79	Two- to eight-year survival rates in patients who refused coronary artery bypass grafting. American Journal of Cardiology, 1989, 63, 155-159.	0.7	11
80	Utility and quality-adjusted life-years in coronary artery disease. Medicine (United States), 2017, 96, e9113.	0.4	11
81	Ten-Year Follow-Up of Off-Pump and On-Pump Multivessel Coronary Artery Bypass Grafting: MASS III. Angiology, 2019, 70, 337-344.	0.8	11
82	Custos comparativos entre a revascularização miocárdica com e sem circulação extracorpórea. Arquivos Brasileiros De Cardiologia, 2008, 91, 369-376.	0.3	11
83	Impact of hypoglycemic agents on myocardial ischemic preconditioning. World Journal of Diabetes, 2014, 5, 258.	1.3	11
84	Hypotheses, rationale, design, and methods for prognostic evaluation of cardiac biomarker elevation after percutaneous and surgical revascularization in the absence of manifest myocardial infarction. A comparative analysis of biomarkers and cardiac magnetic resonance. The MASS-V Trial. BMC Cardiovascular Disorders, 2012, 12, 65.	0.7	10
85	Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. Cost Effectiveness and Resource Allocation, 2018, 16, 55.	0.6	10
86	A randomized comparative study of patients undergoing myocardial revascularization with or without cardiopulmonary bypass surgery: The MASS III Trial. Trials, 2008, 9, 52.	0.7	9
87	Coronary heart disease clinical manifestation and risk factors in Japanese immigrants and their descendents in the city of São Paulo. Arquivos Brasileiros De Cardiologia, 2003, 81, 234-238.	0.3	7
88	Genetic Variants of Diabetes Risk and Incident Cardiovascular Events in Chronic Coronary Artery Disease. PLoS ONE, 2011, 6, e16341.	1.1	7
89	Comparison between off-pump and on-pump coronary artery bypass grafting in patients with severe lesions at the circumflex artery territory: 5-year follow-up of the MASS III trial. European Journal of Cardio-thoracic Surgery, 2015, 47, 455-458.	0.6	7
90	Grande fÃstula bilateral da artéria coronária: a escolha do tratamento clÃnico. Arquivos Brasileiros De Cardiologia, 2009, 93, e48-9.	0.3	6

#	Article	IF	Citations
91	Efficacy of aneurysmectomy in patients with severe left ventricular dysfunction: favorable short-and long-term results in ischemic cardiomyopathy. Clinics, 2010, 65, 947-952.	0.6	6
92	Teratoma of the mediastinum: a case report. Journal of Medical Case Reports, 2011, 5, 193.	0.4	5
93	On-pump versus off-pump coronary artery bypass surgery in patients older than 60Âyears: five-year follow-up of MASS III trial. Journal of Cardiothoracic Surgery, 2014, 9, 127.	0.4	5
94	The cost–effectiveness of strategies in coronary artery disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 805-813.	0.7	5
95	Role of Trimetazidine in Ischemic Preconditioning in Patients With Symptomatic Coronary Artery Disease. Medicine (United States), 2015, 94, e1161.	0.4	5
96	Biomarker release after percutaneous coronary intervention in patients without established myocardial infarction as assessed by cardiac magnetic resonance with late gadolinium enhancement. Catheterization and Cardiovascular Interventions, 2017, 90, 87-93.	0.7	5
97	Myocardial injury in diabetic patients with multivessel coronary artery disease after revascularization interventions. Diabetology and Metabolic Syndrome, 2017, 9, 92.	1.2	5
98	Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: Results from the MASS III trial. International Journal of Cardiology, 2018, 273, 63-68.	0.8	5
99	Coronary Bypass Surgery for Patients with Renal Transplantation. Cardiology, 1986, 73, 151-155.	0.6	4
100	Hypotheses, rationale, design, and methods for evaluation of ischemic preconditioning assessed by sequential exercise tests in diabetic and non-diabetic patients with stable coronary artery disease – a prospective study. BMC Cardiovascular Disorders, 2013, 13, 117.	0.7	4
101	Significant elevation of biomarkers of myocardial necrosis after coronary artery bypass grafting without myocardial infarction established assessed by cardiac magnetic resonance. Medicine (United) Tj ETQq1 1	. 007.8431	4 r g BT /Over
102	Abnormal elevation of myocardial necrosis biomarkers after coronary artery bypass grafting without established myocardial infarction assessed by cardiac magnetic resonance. Journal of Cardiothoracic Surgery, 2017, 12, 122.	0.4	4
103	Conservative strategy for treatment of stable coronary artery disease. World Journal of Clinical Cases, 2015, 3, 163.	0.3	4
104	On-pump versus off-pump coronary artery bypass surgery in patients older than 60Âyears: five-year follow-up of MASS III trial. Journal of Cardiothoracic Surgery, 2014, 9, .	0.4	3
105	Exercise stress testing before and after successful multivessel percutaneous transluminal coronary angioplasty. Brazilian Journal of Medical and Biological Research, 2006, 39, 475-482.	0.7	3
106	The challenge of treating elderly coronary artery disease patients. Journal of Thoracic Disease, 2016, 8, 1434-1436.	0.6	3
107	Coronary to bronchial artery fistula: are we treating it right?. Journal of Invasive Cardiology, 2012, 24, E303-4.	0.4	3
108	A case of mid-apical obstructive hypertrophic cardiomyopathy treated with a transapical myectomy approach: a case report. Journal of Medical Case Reports, 2014, 8, 364.	0.4	2

#	Article	IF	Citations
109	Recurrent Angina Caused by Coronary Subclavian Steal Syndrome Confirmed by Positron Emission Tomography. Annals of Thoracic Surgery, 2015, 99, e111-e114.	0.7	2
110	The Influence of Diabetes Mellitus in Myocardial Ischemic Preconditioning. Journal of Diabetes Research, 2016, 2016, 1-6.	1.0	2
111	Chronic Kidney Disease and Coronary Artery Disease. , 2018, , .		2
112	Long-term prognostic value of late gadolinium enhancement and periprocedural myocardial infarction after uncomplicated revascularization: MASS-V follow-up. European Heart Journal Cardiovascular Imaging, 2020, , .	0.5	2
113	Significant association of SYNTAX score on release of cardiac biomarkers in uncomplicated post-revascularization procedures among patients with stable multivessel disease. Medicine (United) Tj ETQq1 1	0. 084 314	l rgBT /Overl
114	Hypotheses, rationale, design, and methods for prognostic evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy who undergo medical or surgical treatment: MASS-VI (HF). Trials, 2020, 21, 337.	0.7	2
115	Revascularização miocárdica completa, incompleta ou nenhuma. Arquivos Brasileiros De Cardiologia, 2006, 87, e144-e146.	0.3	2
116	Interventional therapies in ischemic ventricular dysfunction: facts and versions!. Annals of Translational Medicine, 2016, 4, S27-S27.	0.7	2
117	Avaliação prognóstica da doença coronária estável através de um novo escore. Arquivos Brasileiros De Cardiologia, 2011, 96, 411-419.	0.3	1
118	Long-term follow-up of a randomized, controlled clinical trial of three therapeutic strategies for multivessel stable coronary artery disease in women. Interactive Cardiovascular and Thoracic Surgery, 2014, 19, 997-1001.	0.5	1
119	Surgical and percutaneous revascularization outcomes based on SYNTAX I, II, and residual scores: a long-term follow-up study. Journal of Cardiothoracic Surgery, 2021, 16, 248.	0.4	1
120	Single Photon Computed Tomography-Myocardial Perfusion Scintigraphy. Diagnostic Tool Anticipating the Disease. Arquivos Brasileiros De Cardiologia, 2018, 112, 129.	0.3	1
121	Ventricular Arrhythmias Induced by Programmed Ventricular Stimulation After Uncomplicated Myocardial Infarction. Angiology, 1992, 43, 578-584.	0.8	0
122	Commentary. Evidence-based Cardiovascular Medicine, 2005, 9, 54.	0.0	0
123	Reply to Athappan and Subramanian. European Journal of Cardio-thoracic Surgery, 2008, 34, 703-703.	0.6	0
124	Hypotheses, rationale, design, and methods for prognostic evaluation in type 2 diabetic patients with angiographically normal coronary arteries. The MASS IV-DM Trial. BMC Cardiovascular Disorders, 2010, 10, 47.	0.7	0
125	COST-EFFECTIVENESS ANALYSIS AND QUALITY OF LIFE OF ON-PUMP AND OFF-PUMP STABLE MULTIVESSEL CORONARY ARTERY BYPASS GRAFTING: MASS III TRIAL 5-YEAR FOLLOW-UP. Journal of the American College of Cardiology, 2017, 69, 100.	1.2	0
126	Differences in lipid transfers to HDL between patients with coronary arterial disease with or without type 2 diabetes mellitus. Atherosclerosis, 2017, 263, e217.	0.4	0

#	Article	IF	CITATIONS
127	APPLICATION OF SYNTAX SCORE I, II AND RESIDUAL SYNTAX AS PREDICTORS OF LONG-TERM CLINICAL OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING. Journal of the American College of Cardiology, 2019, 73, 174.	1.2	0
128	VERY LONG-TERM FOLLOW-UP OF DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING ANGIOPLASTY WITH CONVENTIONAL AND DRUG-ELUTING STENTS. Journal of the American College of Cardiology, 2019, 73, 137.	1.2	0
129	Effect of ischemic preconditioning on cardiovascular outcomes in patients with symptomatic coronary artery disease. Coronary Artery Disease, 2019, 30, 536-541.	0.3	0
130	Lipid transfer to HDL, CETP and HDL composition in coronary artery disease patients with or without type 2 diabetes mellitus. European Journal of Preventive Cardiology, 2020, 27, 2223-2225.	0.8	0
131	Stress Testing and Risk Prediction in People With Known Symptomatic Multivessel Coronary Artery Disease—Reply. JAMA Internal Medicine, 2020, 180, 166.	2.6	0
132	EFFECT OF MYOCARDIAL ISCHEMIA IN DIABETIC AND NON-DIABETIC PATIENTS: LONG-TERM FOLLOW-UP OF MASS REGISTRY. Journal of the American College of Cardiology, 2020, 75, 109.	1.2	0
133	Balloon Aortic Valvoplasty in Patient With Severe Calcific Aortic Stenosis and Cardiogenic Shock. Journal of Medical Cases, 2014, 5, 583-586.	0.4	0
134	Better Technology, More Spending, Worse Outcomes. Arquivos Brasileiros De Cardiologia, 2018, 110, 331-332.	0.3	0
135	Large Bilateral Coronary Artery Fistula: 10-year follow-up in Clinical Treatment. Arquivos Brasileiros De Cardiologia, 2018, 112, 211-213.	0.3	0
136	Behavior of Ultrasensitive C-Reactive Protein in Myocardial Revascularization with and without Cardiopulmonary Bypass. Brazilian Journal of Cardiovascular Surgery, 2018, 33, 535-541.	0.2	0
137	Abstract 13660: Initial Revascularization in Chronic Coronary Syndromes With Myocardial Ischemia. Circulation, 2020, 142, .	1.6	O